Prenuvo Launches Research Network to Enhance Proactive Healthcare

Sept. 29, 2026 — Prenuvo has introduced the Prenuvo Research Network, an initiative that integrates AI tools, research and development teams, scientists, and academic institutions to advance proactive, preventive medicine.

Central to The Network is the Prenuvo Imaging Biobank, comprising over 200,000 high-quality whole-body MRI scans acquired via standardized protocols. This extensive collection enables researchers to investigate disease patterns long before symptoms manifest.

The Network aims to identify early signs of structural and physiological alterations in the human body, providing insights into the progression of non-communicable diseases such as cardiovascular diseases, cancer, metabolic disorders, and neurodegenerative conditions.

Collaborators in the initiative include experts from over 50 institutions, among them City of Hope, UCSF, and Moffitt Cancer Center. Unlike conventional academic research, which often faces delays due to grant cycles and narrow scopes, this Network emphasizes collaborative, clinically relevant inquiries led by Prenuvo's Medical Affairs and AI Research teams.

This effort builds on Prenuvo's research endeavors, including the Hercules and Polaris studies, which assess the effectiveness of whole-body MRI screening for early disease detection. All research adheres to ethical standards, patient safety protocols, data integrity, and regulatory requirements such as institutional IRB reviews.

Dr. Alex Exuzides, VP and Head of Research & Medical Affairs at Prenuvo, stated, "The launch of the Prenuvo Research Network marks a groundbreaking moment for the future of healthcare. We are creating a research ecosystem that unites advanced AI, the largest internal database of whole-body MRI scans, and leading academic institutions, all aimed at enhancing proactive care."

Dr. Cyrus Raji, MD, PhD, noted the importance of high-quality research databases for linking peripheral diseases to increased risks of neurological disorders. Dr. Lary Robinson from Moffitt Cancer Center highlighted the rising lung cancer rates among non-traditional risk populations, emphasizing the importance of studying patients who fall outside current screening guidelines using Prenuvo's data.

Dr. Dan Raz from City of Hope discussed a pilot study that combined whole-body MRI with blood testing for individuals with a family history of cancer. He suggested that whole-body MRI could potentially detect cancers earlier and alleviate patient concerns. Dr. Jacob Young from UCSF pointed out that early detection is critical for conditions with progressive growth, advocating for the use of Prenuvo's datasets to refine patient management strategies.

The network currently features four studies, including:

1. Significant Pulmonary and Mediastinal Findings in Patient Driven MRI Whole Body Screening — This study highlights the detection of clinically significant intrathoracic abnormalities in patients undergoing preventive screening, suggesting a potential role for WB-MRI in detecting cancers beyond guideline eligibility.
2. Incidental Brain Findings in more than 78,000 Individuals — A large-scale examination revealing that 7% of individuals screened had significant brain abnormalities, emphasizing the role of MRI in uncovering actionable neurological issues.
3. Whole-Body Changes Linked to Alcohol Intake — This research explores the associations between alcohol consumption and structural changes across organs in non-alcohol use disorder individuals.
4. Incidental Renal Findings Across 117,826 Scans — This study identifies and characterizes the risk profiles of incidental renal lesions, contributing to the understanding of early renal cancer detection within a large cohort.